Weekly Digest – March 2026 Weekly Digest – March 2026 13 March 2026: Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE Alphamab Oncology has achieved a key regulatory milestone, as […]
Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027 Alphamab Oncology continues to expand its ADC pipeline, announcing […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs Voro Therapeutics has entered a strategic research collaboration with Daiichi Sankyo, […]
Weekly Digest – March 2026 Weekly Digest – March 2026 18 March 2026: Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd Aptamer Group plc has officially entered the fast-growing radiopharmaceutical space, launching a targeted programme built around its Optimer […]
Weekly Digest – March 2026 Weekly Digest – March 2026 9 March 2026: Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo announced that the U.S. FDA has […]
Weekly Digest – March 2026 Weekly Digest – March 2026 09 March 2026: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma Oncopeptides announced that it has secured fast-track designation in Norway for a planned Window-of-Opportunity clinical study evaluating a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 10 March 2026: ProstACT Global Phase 3 study (part 1) achieves primary objectives Telix Pharmaceuticals announced that Part 1 of the global Phase 3 ProstACT Global trial evaluating its investigational […]
Weekly Digest – March 2026 Weekly Digest – March 2026 10 March 2026: AstraZeneca initiates Phase 3 CLARITY-Gastric 02 trial of AZD0901 combo in CLDN18.2+ gastric cancer AstraZeneca has initiated the Phase 3 CLARITY-Gastric 02 trial evaluating Sonesitatug vedotin (AZD0901) […]
